12-Year-Old Patient's Father Slams 'Ghastly' Clinical Trial Bets on Kalshi, Polymarket

For a 12-year-old cancer patient and his family, a clinical trial represents hope and a last chance. For bettors on Kalshi and Polymarket, that same trial is a financial instrument. The collision of these worlds has ignited an ethical firestorm in the healthcare community, with patient advocates and medical researchers decrying the potential for insider trading and the commodification of human suffering.

In early August 2026, prediction market platforms Kalshi and Polymarket ignited a firestorm of ethical criticism by allowing bettors to wager on the outcomes of clinical trials and FDA drug approvals. The move, which the companies tout as a way to aggregate valuable information about drug development, has drawn sharp rebuke from researchers, ethicists, and families of patients, who warn that such markets could invite insider trading and corrupt the very clinical trials that bring new treatments to patients. At the center of the controversy is the story of Joshua Pederson, a humanities professor at Boston University, whose 12-year-old son is currently enrolled in a clinical trial after his cancer returned following a remission. Pederson called the betting “ghastly,” arguing that the platforms fail to account for the human suffering behind a “failed” trial. His son’s experience underscores the profound disconnect between financial speculation and the life-and-death stakes of medical research.

“

In early August 2026, prediction market platforms Kalshi and Polymarket ignited a firestorm of ethical criticism by allowing bettors to wager on the outcomes of clinical trials and FDA drug approvals.

Kalshi, a U.S.-regulated prediction market regulated by the Commodity Futures Trading Commission (CFTC), and Polymarket, a decentralized crypto-based platform operating from overseas, have both expanded into the biomedical arena. They now list contracts on whether a specific clinical trial will meet its primary endpoint or whether the FDA will approve a drug by a given date. Proponents argue that the market-generated odds serve as an efficient public forecast, potentially guiding investors, healthcare providers, and patients. Yet critics contend that such markets are an open invitation for insider trading. Clinical trials involve dozens of insiders—doctors, nurses, data monitors, trial sponsors—who possess material nonpublic information about adverse events, enrollment rates, or interim analyses. By betting on these events, these individuals could profit unscrupulously, or worse, be incentivized to subtly influence outcomes. The integrity of the drug approval process, already under strain from industry pressure, could be irreparably harmed.

The regulatory landscape is murky. While Kalshi’s CFTC license covers event contracts, it is unclear whether clinical trial outcomes qualify as acceptable under the agency’s “public interest” standard. The CFTC has previously rejected or constrained contracts on sensitive events, such as terrorism or assassination. Polymarket, for its part, operates in a legal gray area, using cryptocurrency to circumvent traditional financial rails, and has already faced a CFTC penalty for offering unregistered swaps. The emergence of medical-event contracts now raises the stakes, potentially drawing the attention of the FDA, the Securities and Exchange Commission (SEC), and even the Department of Justice if insider-trading rings materialize. Legal experts suggest that even the perception of tainted trials could slow patient enrollment, reduce voluntary data sharing, and ultimately delay life-saving advances.

For the biopharma industry, the betting markets add a new layer of reputational and operational risk. Clinical trial success rates already hover around 10–15% from Phase I to approval. If market odds begin to influence stock prices—as they likely would—companies could see increased volatility or even manipulation. Short-selling based on leaked interim data via prediction markets could become a new front in market abuse. Meanwhile, patient advocacy groups fear that the commodification of trial results will further erode public trust, especially among communities already skeptical of medical institutions. “A clinical trial failing is a more sanitized euphemism for, people are going to suffer, people are going to die, people are going to have one fewer clinical option available to them,” Pederson said, capturing the moral weight that algorithms and odds cannot quantify.